A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Histologically or cytologically confirmed non-squamous NSCLC * Documented progression of disease (locally recurrent or metastatic) per investigator assessment following first-line treatment with 4-6 cycles of Bevacizumab plus a platinum doublet-containing chemotherapy regimen and a minimum of 2 cycles of Bevacizumab (monotherapy) maintenance treatment prior to first progression of disease * No treatment interruption of Bevacizumab treatment greater than 2 consecutive cycles (42 days) between the start of first-line treatment to start of Cycle 1 of second line treatment * Randomization within 4 weeks of progression of disease * At least one unidimensionally measurable lesion meeting RECIST v1.1 criteria * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Participants with adequate hematological, liver, and renal function * Female participants must not be pregnant or breast-feeding. Female participants of childbearing potential and fertile male participants must agree to use a highly effective contraceptive during the trial and for a period of at least 6 months following the last administration of trial drug(s) Exclusion Criteria: * Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component * Epidermal growth factor receptor (EGFR)-mutation-positive disease according to local laboratory testing * History of hemoptysis greater than or equal to (\>/=) grade 2 within 3 months of randomization * History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding and active gastrointestinal bleeding * Major cardiac disease * Treatment with any other investigational agent within 28 days prior to randomization * Known hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs foreseen * Malignancy other than NSCLC within 5 years prior to randomization and evidence of any other disease that contraindicates the use of an investigational or SOC drug